iShares Biotechnology ETF (NASDAQ:IBB – Get Free Report) was the recipient of unusually large options trading on Monday. Traders acquired 72,196 put options on the company. This represents an increase of approximately 1,389% compared to the average volume of 4,847 put options.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Guardian Wealth Advisors LLC NC increased its position in shares of iShares Biotechnology ETF by 24.8% during the 4th quarter. Guardian Wealth Advisors LLC NC now owns 372 shares of the financial services provider’s stock valued at $49,000 after purchasing an additional 74 shares during the last quarter. Ally Invest Advisors Inc. grew its position in iShares Biotechnology ETF by 5.3% during the fourth quarter. Ally Invest Advisors Inc. now owns 1,515 shares of the financial services provider’s stock valued at $200,000 after buying an additional 76 shares during the period. Arete Wealth Advisors LLC increased its holdings in iShares Biotechnology ETF by 4.2% during the fourth quarter. Arete Wealth Advisors LLC now owns 1,990 shares of the financial services provider’s stock valued at $263,000 after buying an additional 80 shares during the last quarter. TD Private Client Wealth LLC raised its position in iShares Biotechnology ETF by 3.0% in the fourth quarter. TD Private Client Wealth LLC now owns 2,746 shares of the financial services provider’s stock worth $363,000 after acquiring an additional 81 shares during the period. Finally, Cullen Frost Bankers Inc. raised its position in iShares Biotechnology ETF by 1.5% in the fourth quarter. Cullen Frost Bankers Inc. now owns 5,654 shares of the financial services provider’s stock worth $748,000 after acquiring an additional 82 shares during the period. 62.45% of the stock is owned by institutional investors.
iShares Biotechnology ETF Stock Up 0.1 %
iShares Biotechnology ETF stock opened at $134.36 on Wednesday. iShares Biotechnology ETF has a twelve month low of $123.60 and a twelve month high of $150.57. The company has a market capitalization of $6.35 billion, a P/E ratio of 24.52 and a beta of 0.84. The stock’s 50 day moving average is $135.92 and its 200 day moving average is $140.53.
iShares Biotechnology ETF Cuts Dividend
About iShares Biotechnology ETF
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Featured Articles
- Five stocks we like better than iShares Biotechnology ETF
- Earnings Per Share Calculator: How to Calculate EPS
- GitLab: Get In While It’s Down—Big Rebound Ahead
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Tesla Stock: Finding a Bottom May Take Time
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.